Natural Products Insider

SEP-OCT 2017

INSIDER is the leading information source for marketers, manufacturers and formulators of dietary supplements, healthy foods and cosmeceuticals. Since 1997, INSIDER has been serving the needs of the global nutrition industry.

Issue link: http://digital.naturalproductsinsider.com/i/871469

Contents of this Issue

Navigation

Page 20 of 160

14 INSIDER September/October 2017 neurodegenerative disease. "This has very clear relevance to cognitive disorders." Palumbo referenced a 2014 publication as the "fi rst objective evidence that curcumin labels Aβ [amyloid beta] plaques in the retina of pre-Alzheimer's patients." 4 For the study, researchers used curcumin (as Meriva) to determine changes in hyper- or hypo-fl uorescent lesions found via imaging techniques called fundus autofl uorescence (FAF) and optical scanning tomography (OCT) in the retina of patients with mild cognitive impairment. Curcumin caused patchy hypo-fl uorescent FAF to occur (indicates absence of retinal pigment pathology) and spots seemed brighter on OCT, researchers determined. A 2017 research publication further supports the potential for curcumin in treatments of Alzheimer's disease (AD). 5 Researchers used a recently developed nanoplasmonic fi ber tip probe (nFTP) technology to investigate whether curcumin leads to intracellular AD pathologic changes—an effect of curcumin not previously known. "We showed that our nFTP technology could robustly detect intracellular AD- related protein changes caused by a well-known infl ammation inducer and a familial AD mutation," researchers concluded, adding, "Intriguingly, curcumin remarkably reduced the level of intracellular oligomers while [it] modestly reduced the level of an infl ammatory cytokine. Thus, our results provided evidence that curcumin's mechanism of action in attenuating AD pathology is through a major role of decreasing oligomerization." Additional research showed curcumin derivatives displayed a high inhibitory effect on Aβ aggregation 6 and induced the formation of lower molecular size Aβ species that have weaker cell toxicity. 7 In a 24-week, double-blind, placebo- controlled study with a 24-week extension, better tolerability and effi cacy was seen with curcuminoids (as Curcumin C3 Complex ® , from Sabinsa) at the dosage of 2 g/d and 4 g/d when supplemented in subjects with mild-to-moderate AD symptoms. 8 Curcumin prevented decline of cognitive function in a population of community- dwelling, older adults in a 12-month, randomized, placebo-controlled, double- blind study. 9 For the study, 96 participants were administered either 1,500 mg/d curcumin (as BCM-95 ® , from DolCas Biotech LLC) or placebo. A signifi cant correlation between time and treatment was observed for the Montreal Cognitive Assessment. Subsequent analysis revealed Supplements: Curcumin » » » Research is critical to expand the reach of curcumin's healthy effects, and research is being conducted to support the benefits of curcumin across several health categories.

Articles in this issue

Archives of this issue

view archives of Natural Products Insider - SEP-OCT 2017